Boehringer Ingelheim and NIPER Hajipur Partner to Strengthen India’s Biopharma Ecosystem

#PharmaInnovation #ViksitBharat #NIPERHajipur #BoehringerIngelheim #BiopharmaSHAKTI #HealthcareIndia #AcademicCollaboration

"The greater the number of talented Indian researchers engaged in this mission, the stronger the outcomes for the country." - Meenal Gauri, Managing Director - Boehringer Ingelheim India

May 2026 : To transform the scientific ecosystem in Bihar, Boehringer Ingelheim India and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur have signed a five-year Memorandum of Understanding (MoU) to accelerate drug discovery and high-level academic exchange.

The agreement was formalized in the presence of Shri Manoj Joshi (IAS), Secretary, Department of Pharmaceuticals. This partnership isn't just about corporate social responsibility; it is a strategic alignment with the Indian government’s Biopharma SHAKTI initiative - a ₹10,000-crore mission aimed at evolving India from the "pharmacy of the world" into a global hub for innovative biopharmaceuticals.

At the heart of this collaboration is the opnMe® portal. Through this platform, Boehringer Ingelheim provides NIPER researchers with free access to over 150 well-characterized pre-clinical tool compounds. This effectively levels the playing field, allowing local students and faculty to work with the same high-caliber molecules used by elite labs globally.

Reflecting on the importance of this synergy, Shri Manoj Joshi noted that India's pharmaceutical sector is "steadily transitioning from a volume-driven model to a value-driven, innovation-led ecosystem, supported by targeted policy interventions, infrastructure development, and stronger industry-academia linkages, in alignment with the national vision of Viksit Bharat 2047."

For NIPER Hajipur, this represents a massive leap in regional capability. Prof. K. Ruckmani, Director, NIPER Hajipur, emphasized the geographical impact: "NIPER Hajipur sits at the heart of one of India’s most populous regions, and our mandate is to build pharmaceutical research and talent capability that serves Bihar, eastern India and the country at large."

Meenal Gauri, Managing Director of Boehringer Ingelheim India, echoed this sentiment of empowerment, stating: "The greater the number of talented Indian researchers engaged in this mission, the stronger the outcomes for the country."

By bridging the gap between classroom theory and industry-grade R&D, this non-commercial partnership ensures that the next generation of Indian scientists is ready to tackle the world’s most pressing health challenges.

Pro MFG Media Newsletter

Get regular manufacturing insights that matter and enable business.